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A number of countries now include meningococcal vaccines in their routine immunization programs. This
review focuses on different approaches to including meningococcal vaccines in country programs across
the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by pre and
post-vaccine incidence rates in the last 20 years. Mass campaigns using conjugated meningococcal
vaccines have lead to control of serogroup C meningococcal disease in the UK, Canada, Australia, Spain,
Belgium, Ireland, and Iceland. Serogroup B disease, predominant in New Zealand, has been dramatically
decreased, partly due to the introduction of an outer membrane vesicle (OMV) vaccine. Polysaccharide
vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and
Egypt. The highest incidence region of the meningitis belt initiated vaccination with the serogroup A
conjugate vaccine in 2010 and catch-up vaccination is ongoing. Overall results of this vaccine introduction
are encouraging especially in countries with a moderate to high level of endemic disease. Continued
surveillance is required to monitor effectiveness in countries that recently implemented these programs.
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Introduction
Neisseria meningitidis is one of the leading causes of
bacterial meningitis globally. The annual number of
cases related to invasive meningococcal disease
(IMD) is estimated to be at least 1.2 million with
135 000 deaths.1 To combat IMD, an increasing
number of countries have included vaccines against
N. meningitidis in their routine immunization pro-
grams. These include polysaccharide and conjugate,
monovalent and polyvalent vaccine against ser-
ogroups A, C, W, and/or Y, and outer membrane
vesicle (OMV) vaccines against serogroup B. The
specific vaccine use in each country depends on the
predominant serogroups, cost, and availability. The
impact of these vaccines has been documented in
several countries with reliable surveillance systems,
and includes a direct decrease in incidence rates as
well as indirect benefits due to induction of herd
protection. This review presents evidence of the
impact that different vaccines have had globally and
includes safety and efficacy data for recently intro-
duced vaccines.
Methods
Search strategy and selection criteria
Our sources for the latest vaccine related data included
the National Library of Medicine (PubMed), the
WHO website of the Weekly Epidemiological Record,
and the European Centre for Disease Prevention and
Control. We searched PubMed with the following key
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terms: (‘Neisseria meningitidis’) OR (‘meningococcal’)
OR (‘meningococcemia’) OR (‘meningococcus’). The
search was limited to studies of people, studies
published in English, and published from 1 Jan 1990
to 31 Dec 2010; the initial search yielded 5336 results.
In addition, data were obtained from WHO’s publica-
tions in the Weekly Epidemiological Record (WER)
for the latest figures from 14 African meningitis belt
countries. The European Union Invasive Bacterial
Infections Surveillance Network (EU-IBIS), which is
now maintained by the European Centre for Disease
Prevention and Control, was accessed for updated
results from European countries. We searched refer-
ences of identified articles for additional articles, and
reviewed abstracts and titles and selected studies if we
thought they were relevant to this review.
Types of Vaccines
Currently available meningococcal vaccines against
serogroups A, C, W, and Y include both polysac-
charide vaccines and polysaccharide–protein conju-
gate vaccines based on the meningococcal capsule.
For serogroup B, vaccine development has included
protein vaccines based on meningococcal OMV,
while more recently a range of conserved proteins
including Factor H Binding Protein (fHBP),
Neisseria Adhesin A (nadA), and Neisseria Heparin
Binding Antigen (NHba) have been used as vaccine
components. One of the candidates serogroup B
vaccines has three components, two of which are
fusion proteins (Genome derived Neisseria Antigens
– GNA 2091 fused with fHBP and NHba fused with
GNA 1030). The third component is recombinant
nadA. Different aspects of the immune response to
polysaccharide and conjugate vaccines are compared
in Table 1.
Polysaccharide Meningococcal Vaccines
There are several combinations of polysaccharide
vaccines used globally, including bivalent (A, C),
trivalent (A, C, W), and quadrivalent (A, C, Y, W)
vaccines. The first polysaccharide vaccines containing
high molecular weight polysaccharides suitable for
vaccines were developed at Walter Reed Army
Institute and used in military recruits to prevent
recurrent outbreaks among newly recruited soldiers
in 1960s.3,4 Polysaccharide meningococcal vaccines
are proven to be immunogenic and safe. They are
highly effective in closed populations of adults at
high risk for disease, including military recruits
and household contacts of affected individuals5–7
and in outbreak control.8 Serogroup A polysacchar-
ide vaccine has also been used effectively during
outbreaks in Africa.9–11
The major disadvantage of polysaccharide vaccines
are their inability to produce memory cells leading to
poor response to booster and short duration of
protection. Hypo-responsiveness (as defined by
impaired serum anticapsular antibody responses to
subsequent vaccine doses) to serogroup C polysac-
charide vaccine in infancy has been shown, especially
if doses are repeated more than once. This hypo-
responsiveness has not been shown by the use of
meningococcal C conjugate (MCC).12
Although a few countries had a routine vaccination
program with polysaccharide vaccines prior to the
development of conjugate vaccines (Syria, Saudi
Arabia), they have been used typically to protect
persons at increased risk for disease, e.g. following
splenectomy, travelers to the annual Muslim pilgrim-
age (Hajj), or in reactive vaccination campaigns in
response to outbreaks. Polysaccharide meningococcal
vaccines are still used for routine immunization in
China and Egypt. In China, serogroup A polysac-
charide vaccine was used in the routine immunization
program since 1982, though the bivalent (A, C)
polysaccharide vaccine was introduced in 2005 after
the serogroup C outbreaks.13
Conjugate Meningococcal Vaccines
Meningococcal conjugate vaccines were introduced in
1999 with the initial introduction of MenC conjugate
vaccines in the UK. Since then, conjugate quad-
rivalent (A, C, Y, W) and monovalent MenA
vaccines have been licensed in various countries.
Currently, 21 countries have introduced conjugate
vaccines into their routine vaccination schedules
(Table 3). Conjugate vaccines use a carrier protein
to present the polysaccharide antigen to the immune
system, in a manner that induces a T-cell immune
response. Ten years of experience in countries with
adequate surveillance systems have shown conjugate
vaccines have a good safety profile and vaccine
Table 1 Overview of the broad immune response to polysaccharide and conjugate vaccines2
Polysaccharide Conjugate
Immunogenicity Adults High High
Infants Low High
Quality of antibodies Avidity Low High
Serum bactericidal antibody (SBA) Low High
Response to booster Poor High
Induction of immunologic memory No High
Reduction of colonization No Yes
Duration of protection Short Moderate
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efficacy (VE). However, questions remain regarding
long-term effectiveness of conjugate vaccines and
how to optimize vaccination programs. Table 2
depicts different licensed conjugate vaccines with
relevant references on effectiveness, immunogenicity,
and safety, as well as most commonly used schedules.
Vaccine efficacy varies by the conjugate vaccine
used and specific program implementation, but is
higher in older children and adolescents compared to
young children, with studies reporting short term VE
as high as 97% for MenC vaccine in teenagers. Short
term VE was high (83%) in infants and pre-school
aged children who received immunization but
declined with time. Estimates of VE over time in
those vaccinated in infancy fell from 95% in the first
year to 31% by the fourth year after vaccination.29–31
In the United States, initial VE estimates of 75% were
found with MenACWY vaccine in adolescents with
rapid waning even in teenagers who were expected to
have higher efficacy.14
Another measure of the effectiveness of the
meningococcal conjugate vaccination programs are
their herd effects. Two years after introduction of
MCC vaccine in the UK, the serogroup C carriage
rate was reduced by 81%.32 Attack rates among
unvaccinated children and adults in the UK declined
by more than 67% in the 4 years following vaccine
introduction. Between 1998 and 2009, the incidence
of serogroup C disease in persons over 25 years
dropped from 0.55/100 000 persons to 0.02/100 000
persons in the UK (96% decrease); and the number of
cases in infants under 3 months of age dropped from
13 in 1998 to 1 in 2009 (92% decrease).26–28 These
effects were seen despite a declining seroprevalence
of protective antibodies among younger vaccinated
cohorts as early as 18 months after the last scheduled
dose of vaccine.33
Recently, a vaccine, 4CMenB (BexseroH), contain-
ing three recombinant proteins, and OMV derived
from a serogroup B meningococcal strain (MenB) has
been licensed in Europe and Australia and is indicated
for persons aged 2 months or older. UK’s Joint
Committee on Vaccination and Immunisation (JCVI)
has taken an interim position to not recommend
Bexsero for routine vaccination at this time. Further
information will be provided early next year. It has
been shown to be safe in adolescents and infants.
However, up to 80% of infants have experienced fever,
particularly when 4cMenB was concomitantly given
with routine vaccines.34
MenC Conjugate Vaccines
Meningococcal C conjugate vaccine was first licensed
in the UK based on antibody response studies, but
without pre-licensure Phase III clinical trials. Several
vaccine products are now licensed, conjugated toT
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tetanus toxoid, diphtheria toxoid or CRM-197.
Multiple studies have since evaluated the safety and
immunogenicity of MCC vaccination in several
countries. Studies in healthy adults show a significant
rise in GMT after vaccination.35 Similar results have
been seen in healthy adolescents.36 At least five
studies found MCC to be safe, with no major adverse
reactions and only minor local reactions.37–41
Immunogenicity studies have shown MCC to be
immunogenic in infants as well. However, prior to
moving the third dose to 12 months of age in the UK,
Borrow, et al. found only 8–12% of children who had
completed a three dose series in infancy to have rSBA
titers §1:8 by 4 years of age, with GMTs similar to
pre-vaccination levels.42 In a phase four clinical trial
of 250 children in the UK, rSBA titers were tested
6 years after the primary MCC series. Age at priming
ranged from 2 months to 6 years. Only 25% (CI
20%–30%) of all children had protective titers §1:8.
A booster was highly effective in this cohort and
resulted in titers of 1:8 in 99.6% of participants
measured 1 year after the booster dose.43
Recent data from the United Kingdom indicate
that the memory response may not be rapid enough to
protect against meningococcal disease following expo-
sure through a close contact. After initial priming with
monovalent MenC conjugate vaccine, a memory
response after a booster dose is not measurable until
5–7 days. The incubation period of meningococcal
disease is usually less than 3 days. Auckland, et al.
have reported 53 cases of vaccine failure, largely in
healthy children who had received a primary vaccina-
tion series in infancy. All cases mounted an anamne-
stic immune response.44 Therefore, while a memory
response may protect some individuals from disease or
decrease disease severity, already present circulating
antibody may be a more important indicator of direct
long-term protection against meningococcal disease.
Antibody responses were similar when MCC was co-
administered simultaneously with other routine infant
immunizations.45–47
Further studies have shown that a two dose series
at 3 and 5 months yields equivalent immunity.46,48,49
In summary, implementation of meningococcal
conjugate vaccination programs, in countries across
Europe, North America, and Australia, have all
documented a reduction in serogroup C incidence. In
the UK, incidence has decreased by 97% since 1998.
The number of deaths from serogroup C disease
declined from 78 in 1998 to 1 in 2009.49 In Canada,
incidence declined by 65%, 5 years after implementa-
tion. Ontario saw a 16% reduction per year in
serogroup C disease among persons §20 years of
age from 2000 to 2006 after introducing an MCC
vaccination program in adolescents and infants.50 No
such reduction was seen in other serogroups that were
not included in the vaccine.51 Reductions in disease
incidence have also been recorded in Australia,
Netherlands, Spain, and Greece.52–55
Since the introduction of the meningococcal C
(MenC) vaccination program in UK in November
1999, the vaccine schedule has undergone changes.
Following the introduction of the vaccine, all
children and adolescents under the age of 18 were
offered immunization over the subsequent 2-year
period. In 2002, the catch-up campaign was extended
to include adults less than 25 years of age.56 In 2006,
the primary immunization course was changed to two
doses at 3 and 4 months of age, and a booster dose at
12 months of age. This was based on studies that
showed that protection waned in the second year of
life.29,56,57 In July 2013, the UK implemented further
changes to the schedule to maintain the success of the
MenC vaccination program in the UK. This followed
the recommendations from the UK Joint Committee
on Vaccination and Immunisation (JCVI), based on a
study that showed that a single dose in infancy was
sufficient to provide protection in the first year of life, to
remove the second dose given at 4 months of age from
the schedule. JCVI also recommended the introduction
of an adolescent booster to extend protection into early
adulthood. Other countries that introduced the vaccine
in later years have followed similar schedule changes
based on the experience of the vaccine in UK. The
MenC vaccine was introduced in Australia in 2003 as a
single dose for all children less than 12 months of age.
From 1 July 2013, the combined Haemophilus influen-
zae type b (Hib) and meningococcal serogroup C
(MenC) vaccine, MenitorixH, was added to the
National Immunisation Program (NIP) schedule at
12 months of age.
Quadrivalent Meningococcal Conjugate
Vaccines
In 2005, the first quadrivalent meningococcal con-
jugate vaccine (A ,C, W, Y) conjugated to diphtheria
toxin (Menactra by Sanofi Pasteur) was licensed by
the US Food and Drug Administration. A second
MenACWY vaccine conjugated to CRM-197
(Menveo by Novartis) was licensed in 2010 and
Nemenrix by GSK was licensed in 2012. In pre-
licensure clinical studies, all these vaccines were
found to be safe and immunogenic. In the United
States these vaccines are licensed for the age 2–
54 years, with studies evaluating a multiple dose
series in infants and toddlers ongoing.
MenA Conjugate Vaccine
While meningococcal conjugate vaccines have the
attributes needed to eliminate epidemic meningitis in
Africa (including eliminating carriage of the organ-
ism), monovalentMenA conjugate C vaccines were not
available earlier whereas quadrivalent meningococcal
Ali et al. Meningococcal vaccine
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conjugate vaccines were costly and there was no
development plan to license them in Africa. The
Meningitis Vaccine Project was initiated in 2001 as
collaboration with multiple partners, core partners
being WHO and PATH, to bring an affordable
conjugate vaccine targeting serogroup A to the
African Meningitis Belt.
In 2010, a meningococcal A conjugate vaccine
(MenAfriVac), manufactured by the Serum Institute
of India, was licensed and subsequently prequalified
by WHO. In September 2010, MenAfriVac was first
introduced in mass vaccine campaigns in Burkina
Faso, Mali, and Niger. All persons aged 1–29 years
were vaccinated in the selected districts included in
these initial campaigns, followed by nationwide
campaigns in December 2010.
This vaccine has been shown to be highly immuno-
genic with a safety profile comparable to the safety
profile of polysaccharide vaccine.58 The conjugate
vaccine-induced functional antibody response against
meningococcal serogroup A was significantly higher
and more persistent than that induced by a poly-
saccharide vaccine. In addition, the conjugate vaccine
also induced immunologic memory. Recent studies
have shown disappearance of serogroup A Neisseria
meningitides carriage among both vaccinated and
unvaccinated populations which is consistent with a
vaccine-induced herd protection effect.52,58 A study
conducted in Burkina Faso has proved the effective-
ness of the MenAfrivac vaccine as no serogroup A
carriage was identified after vaccination compared to a
baseline serogroup A carriage prevalence of 0.39%.52
MenB OMV Vaccines
While progress toward reducing meningococcal dis-
ease globally has been made with meningococcal
conjugate vaccines for serogroups A, C, Y, and W,
vaccines to protect against various strains of ser-
ogroup B disease have presented a challenge because
the B polysaccharide is not immunogenic and other
potential antigen targets are highly diverse. Sero-
group B vaccines have been developed for specific
outbreak strains using the OMV specific to that
strain, including vaccines to target disease in New
Zealand and Cuba.59,60 These vaccines are immuno-
genic, but require multiple doses, especially in young
infants, and efficacy appears to have a short duration
of protection.61 Efforts to find novel vaccine antigens
to protect against serogroup B disease have identified
several protein surface antigens. Efficacy of a new
vaccine using sub-capsular protein has been estab-
lished in infants in several clinical trials.62,63 To
predict regional strain coverage of this vaccine, a
Meningococcal Antigen Typing System (MATS) has
been employed in five European countries.64,65 This
approach has been supplemented with studies using a
more accepted correlate or protection, SBAs, and
pooled serum from vaccines. Another vaccine that
targets conserved antigens is currently under investi-
gation in clinical trials. These vaccines may have
the potential to protect not only against serogroup
B disease but against other serogroups as well.
Preliminary data from these trials are promising, but
the role these vaccines will play in controlling
meningococcal disease remains to be determined.
Research in Norway has suggested that although the
MenB OMV vaccine conferred protection against
group B meningococcal disease, the effect is not
sufficient to justify the cost of a public vaccination
program.66 However, a recent study in Normandy
showed that MenB vaccination was associated with a
lower carriage rate among vaccinated children (0.31%)
as compared to unvaccinated children (2.10%) indicat-
ing that meningococcal OMV-based vaccines reduce
meningococcal carriage and may hence confer herd
protection.67The population impact of these vaccines is
likely to be key in determining the cost-effectiveness,
and therefore in overcoming barriers to introduction.67
Current Utilization of Meningococcal Vaccines in
Routine Immunization Programs
Table 2 lists the countries that have included
meningococcal vaccines in their routine immuniza-
tion programs along with their year of introduction,
vaccination schedule, and any special recommenda-
tions. Pre and post vaccination attack rates per
100 000 population, where available, have been
included.
Economic Evaluations of Meningococcal Disease
and Vaccines
Data on the cost of vaccine and financial burden of
disease have been published from Africa and some
industrialized countries where a vaccine has been
introduced. Limited data on meningococcal carriage
and incidence are available from other countries,
especially in Asia, and thus cost effectiveness cannot
currently be accurately determined for these countries.
One study in Burkina Faso found that the cost per
household of a case of meningococcal disease in Sub-
Saharan Africa is US$ 90, with additional US$154
expenditure if sequelae of the disease occur. The
urban cost is more than 200% higher than the rural
cost.85 An idea of the overall burden of disease can be
gaged from the total cost of the 2006–2007 outbreak,
in Burkina Faso which was US$ 9.4 million, 7.1M
borne by the public health system and 2.3M borne by
households which comprised 34% of the GDP
capita.83 The Meningitis Vaccine Project has the
potential to:
N Prevent 123 000 deaths by 2018
N Prevent permanent disability in 287 000 children and
adults
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N Prevent 11 million DALYs lost
N Save approximately $99.7 million in medical costs for
diagnosis and treatment
Cost Effectiveness of Men C Conjugate Vaccine
Six countries reported economic evaluations before
the introduction of MCC vaccines (Australia, Canada
(Quebec), TheNetherlands,UK, Portugal, and Switzer-
land). All of them recommended that one dose in the
second year of life was more cost-effective than a
three-dose infant schedule.84 Further development of
the dynamic model was undertaken after vaccine
introduction to predict the impact of the meningococ-
cal vaccination program and its cost effectiveness in
the UK.86 Various factors feed into this dynamic
model, including the high transmissibility of the disease,
the role of carriage/colonization and possibility of
recurrent colonization with different serotypes, interac-
tion between related bacteria, and the differing risks
of colonization and disease at different ages. The model
accurately reflected the trends of meningococcal disease
in the UK when it was applied retrospectively to the
actual experience in the UK from 1998 to 2004. It was
also able to predict the significant herd protection that
has been seen with the use of this vaccine. The UK
model was also used to investigate the impact of vaccine
schedules in the UK and Spain.82
Fractional Doses
There has been concern that in the event of a large
scale epidemic in the African meningitis belt, the
supply of meningococcal vaccines may not be enough
to match the demand. Thus, a trial was conducted to
test the hypothesis that fractional doses of ACWY
meningococcal polysaccharide vaccine confer for
each serogroup in the vaccine an immunogenic
response, which is non-inferior to the full dose
licensed vaccine(s) in the population targeted during
mass vaccination campaigns in Africa. The objective
of the trial was to measure the immunogenicity of
each component of a dose corresponding to 1/5th and
1/10th of the amount of the current licensed vaccine.
This was a randomized, single-blind, non-inferiority
trial, in which healthy subjects aged 2–20 years in
Uganda were enrolled.87
In the non-immune population, the immunogeni-
city of the 1/5th dose for serogroups A, W, and Y was
non-inferior compared to full dose. In the ITT and
PP analysis, the immunogenicity of 1/5th dose for
serogroupsW and Y was non-inferior compared to full
dose. The immunogenicity of 1/5th dose was inferior to
full dose for serogroup C. With the 1/10th dose, the
antibody titers generated were lower compared to 1/5th
dose, however, it was still non-inferior to full dose for
serogroups W and Y.
In the event of an acute shortage of meningococcal
vaccines during an epidemic, 1/5th or 1/10th of the
normal dose of ACWY polysaccharide vaccine can be
considered depending on the serogroup causing the
epidemic. However, since the absolute titers gener-
ated by the fractionated doses are lower compared to
the full dose, the duration of protection provided by
the fractionated doses is likely to be shorter than the
full dose.
Conclusion
All countries considering the use of meningococcal
vaccines should develop the surveillance infrastruc-
ture for monitoring IMD including clinical case
definition, field investigation, and access to laboratory
capacity for the diagnosis and characterization of N.
meningitidis. The choice of vaccine for each country
should depend on the serogroup(s) (or serosubtype
in case of serogroup B for OMV vaccines) of N.
meningitidis that are locally prevalent. In general,
conjugate vaccines are preferred to polysaccharide
vaccines due to their impact on decreasing nasophar-
yngeal carriage of N. meningitidis and their overall
increased immunogenicity in children. However, in
some countries the high cost of conjugated vaccines
may be prohibitive, and polysaccharide vaccines are
acceptable in those settings.
Countries with a high endemic rate of IMD (.10
cases/100 000 population per year in a country or
large region), other than serogroup B, should use an
appropriate meningococcal vaccine against ser-
ogroups A, C, W, and/or Y in their populations for
prevention and/or outbreak response. In most high
endemicity countries, the peak disease incidence is
in young children and adolescents. Therefore, the
recommended strategy is initial mass vaccination of
young children through adolescents depending on the
country-specific age distribution of disease, followed
by a routine vaccination program with conjugate
vaccination in previously unvaccinated young chil-
dren. Continued surveillance of IMD should dictate
the need and timing of repeat mass vaccination
campaigns.
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